✦ LIBER ✦

PCN35 A COST UTILITY ANALYSIS OF FULVESTRANT VERSUS EXEMESTANE IN THE SECOND LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER IN GREECE (PRELIMINARY RESULTS)

✍ Scribed by M Pangali; A Christodoulopoulou; A Ardavanis; V Barbounis; E Galani; D Skarlos

Book ID: 118607543
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 64 KB
Volume: 8
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)67273-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A comparison of fulvestrant and the thir

A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer

✍ David Dodwell; Ignace Vergote 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 317 KB

Fulvestrant (Faslodex™) versus anastrozo

Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

✍ L. Mauriac; J.E. Pippen; J. Quaresma Albano; S.Z. Gertler; C.K. Osborne 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 196 KB

First results of a randomized phase III

First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) — EORTC 10951 in collaboration with the exemestane working group and NCIC Clinical Trials Group

✍ R Paridaens; P Therasse; L Dirix; L Beex; M.J Piccart; D Cameron; T Cufer; K Roo 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 172 KB

PCN34 COST-EFFECTIVENESS OF ANASTROZOLE

PCN34 COST-EFFECTIVENESS OF ANASTROZOLE OVERTAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER FROM A UK NATIONAL HEALTH SERVICE PERSPECTIVE: THE 5-YEAR COMPLETED TREATMENT ANALYSIS OF THE ATAC TRIAL

✍ R Brown; A Benedict; R Mansel 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Anastrozole versus megestrol acetate in

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma : Results of a survival update based on a combined analysis of data from two mature phase III trials

✍ Aman U. Buzdar; Walter Jonat; Anthony Howell; Stephen E. Jones; Carl P. Blomqvis 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 2 views

Medical University of BACKGROUND. This report presents the results of a survival update based on the combined data from two studies that compared the efficacy and tolerability of anastrozole (1 or 10 mg once daily), a selective, nonsteroidal aromatase inhibitor administered orally, and megestrol ace

Cost-effectiveness analysis of anastrozo

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial

✍ Gershon Y. Locker; Robert Mansel; David Cella; Deborah Dobrez; Sonja Sorensen; S 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 267 KB